Oncology Upward Investment (OUI) jury awards Mablink
On October 14, during the MATWIN board meeting, Mablink’s COO Valérie Attuil was pitching in front of a panel of investors as part of the 2nd Oncology Upward Investment event. …
Mablink adopts Agatha Software solutions
Mablink is adopting Agatha’s solution, a global leader in quality and content management solutions for life sciences.
Mablink is an awardee of the CLARA Proof of Concept Program 2019
Mablink receives the support of the Canceropole CLARA to push forward the development of its ADC platform
Mablink receives iLab 2019 Award
Mablink receives the iLab 2019 award in the presence of French Minister of Higher Education, Research and Innovation, Mrs Frédérique Vidal, and Bpifrance, at the innovation awards ceremony in Paris.
Mablink is incubated and supported by PULSALYS
Mablink receives a €380,000 equity investment from TTO PULSALYS to carry out the preclinical proof of concept of its ADC drug candidate MBK-102 in Non-Hodgkin’s Lymphoma.
Mablink has been awarded the R2B Onco 2019 Trophy
With more than 700 participants last April 4th/5th, the Auvergne-Rhône-Alpes Cancer Research Forum is one of the most federating events. During this event took place the Research2Business (R2B) Oncology Meeting …
Mablink earned the French Tech Seed Label
French Tech Seed labeled company. Our company has recently been granted with the French Tech Seed label which rewards DeepTech projects lead by young dynamic companies. Our highly potent technology …